Stacy Sumpter
Family Medicine · St George, UTNPI 1518922913
Payments from drug & device makers
Across 97 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$428
- Amgen$213
- Astellas Pharma US Inc$192
- Biohaven Pharmaceuticals, Inc.$184
- Boston Scientific$143
- Pfizer$107
- plus $743 from 19 others
What the payments were for
- Food & beverage$1,80590%
- Education$20410%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 22 | $428 |
| Amgen(2 entities) | 10 | $213 |
| Astellas Pharma US Inc | 2 | $192 |
| Biohaven Pharmaceuticals, Inc. | 7 | $184 |
| Boston Scientific | 7 | $143 |
| Pfizer | 6 | $107 |
| AstraZeneca | 6 | $100 |
| Merck | 5 | $76 |
| Boehringer Ingelheim | 4 | $70 |
| Lilly USA, LLC | 4 | $63 |
| Organon | 3 | $56 |
| Inspire Medical Systems, Inc. | 2 | $51 |
| IBSA Pharma Inc. | 3 | $50 |
| Lucid Diagnostics Inc. | 2 | $50 |
| Exact Sciences | 3 | $45 |
| Johnson & Johnson | 2 | $38 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Grifols USA, LLC | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$109
How this compares
$2,009 in reported general payments places this provider in the 70th percentile of 928 family medicine providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 67 | $71,966 |
| EliquisApixaban | 55 | $64,582 |
| XareltoRivaroxaban | 28 | $42,512 |
| TrulicityDulaglutide | 34 | $41,469 |
| MyrbetriqMirabegron | 27 | $31,951 |
| OzempicSemaglutide | 24 | $30,898 |
| JanuviaSitagliptin Phosphate | 28 | $26,951 |
| JardianceEmpagliflozin | 18 | $19,170 |
| RybelsusSemaglutide | 14 | $18,741 |
| Xigduo XrDapaglifloz Propaned/Metformin | 21 | $18,181 |
| FarxigaDapagliflozin Propanediol | 16 | $17,428 |
| TradjentaLinagliptin | 16 | $12,235 |
| Levothyroxine Sodium | 1,036 | $11,277 |
| Liothyronine Sodium | 164 | $7,088 |
| Rosuvastatin Calcium | 488 | $5,979 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $63 | $113,434101 claims |
| PfizerEliquis | $107 | $64,58255 claims |
| Novo NordiskOzempic, Rybelsus | $17 | $49,63938 claims |
| Johnson & JohnsonXarelto | $38 | $42,51228 claims |
| Astellas Pharma US IncMyrbetriq | $192 | $31,95127 claims |
| Boehringer IngelheimJardiance, Tradjenta | $70 | $31,40434 claims |
| MerckJanuvia | $76 | $26,95128 claims |
| AstraZenecaFarxiga | $100 | $17,42816 claims |
| AbbVieSynthroid, Armour Thyroid | $428 | $7,705102 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $21 | $1,91340 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 928 family medicine providers in Utah.
Other family medicine in St George
- Jonathan HubbardSt George$683K
- Thomas CallahanSt George$202K
- Gregory WingerSt George$76K
- John HemmersmeierOgden$24.9M
- Judith KirsteinWest Jordan$22.7M
- Matthew JohnstonSalt Lake City$20.9M
- Jared ProbstSalt Lake City$18.8M
- Bryce PetersonBountiful$16M
- Sarang YoonSalt Lake City$9.4M
- Michael AdamsSandy$8.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.